ArticlePharmaceutical research2026
Development of a Novel Curcumin-Vanillic Acid Eutectic: Physicochemical Characterization, Antioxidant Activity, and Bioavailability Enhancement.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurcumin, a well-known phyto-nutraceutical with broad therapeutic potential, faces critical formulation challenges, including poor aqueous solubility, low dissolution rate, and limited tablettability, leading to poor oral bioavailability and reduced therapeutic efficacy. This study presents a novel curcumin-vanillic acid eutectic system designed to overcome these limitations through a sustainable and green formulation approach.
methodsVanillic acid, a natural phenolic compound with potent antioxidant properties, was selected as a coformer based on in silico analysis demonstrating structural compatibility and potential therapeutic synergy with curcumin. The eutectic mixture was prepared via solvent-free solid-state grinding and characterized using X-ray diffraction, differential scanning calorimetry, Fourier-transform infrared spectroscopy, and proton/carbon nuclear magnetic resonance. Physicochemical, tablettability, and antioxidant properties were subsequently evaluated. DoE software was used to optimize the eutectic-based tablet formulation, followed by its pharmacokinetic evaluation.
resultSpectroscopic results supported eutectic formation, showing modifications in the solid-state characteristics of curcumin accompanied by a lower melting point. These modifications yielded significant improvements in solubility (tenfold, eightfold, and 11-fold in water, buffer pH 1.2, and buffer pH 6.8) and tablettability relative to pure curcumin. The eutectic also exhibited enhanced antioxidant activity (p < 0.05), which may be attributed to the combined intrinsic antioxidant properties of the drug and coformer compared to pure curcumin. DoE-optimized eutectic tablets suggested an enhanced bioavailability of curcumin compared to conventional curcumin tablets; however, warranting confirmation in a larger sample size.
conclusionOverall, the curcumin-vanillic acid eutectic represents a promising formulation approach for developing high-performance phyto-nutraceutical systems.
Indexed as
Identifiers
41927965What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.